Holen Sie sich die Stockscreener-App
22.64
2.56%
0.565
Handel nachbörslich:
22.64
Schlusskurs vom Vortag:
$22.07
Offen:
$21.78
24-Stunden-Volumen:
456.92K
Relative Volume:
1.26
Marktkapitalisierung:
$336.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.70%
1M Leistung:
+47.68%
6M Leistung:
-27.13%
1J Leistung:
+0.00%
1-Tages-Spanne:
$21.51
$23.89
1-Wochen-Bereich:
$21.34
$25.35
52-Wochen-Spanne:
$14.44
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Firmenname
Neurogene Inc
Sektor
Branche
Telefon
(877) 237-5020
Adresse
535 W 24TH STREET, NEW YORK
Vergleichen Sie NGNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
22.64 | 336.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-21 | Eingeleitet | William Blair | Outperform |
| 2024-01-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-05 | Eingeleitet | Stifel | Buy |
| 2024-01-04 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Neurogene Inc Aktie (NGNE) Neueste Nachrichten
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene files to sell 4M shares of common stock for holders - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out - AccessWire
Neurogene Inc. sees significant stock purchases by Samsara BioCapital - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene CEO Rachel McMinn acquires $968,999 in stock By Investing.com - Investing.com UK
Neurogene retains stock target, buy rating amid Rett syndrome trial data - Investing.com Canada
Insider Buying: Christine Cvijic Acquires 24,000 Shares of Neuro - GuruFocus.com
Neurogene president buys $491,400 in company stock By Investing.com - Investing.com Nigeria
Neurogene president buys $491,400 in company stock - Investing.com
Neurogene CEO Rachel McMinn acquires $968,999 in stock - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Shareholders to Inquire about Securities Investigation - AccessWire
Neurogene retains stock target, buy rating amid Rett syndrome trial data By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Patient dies in Neurogene trial - The Pharma Letter
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Investors to Connect - AccessWire
BMO Capital Markets Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week - MSN
Jennison Associates LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright - Defense World
Neurogene patient dies in drug trial, stock surges after FDA says ‘use lower dose’ - Mugglehead
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - MedCity News
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Stockholders to Inquire about Securities Investigation - AccessWire
Patient dies in Neurogene’s Phase I/II Rett syndrome trial - Yahoo Finance
Neurogene drops high-dose arm in Rett study after death - pharmaphorum
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial - Yahoo Finance
Neurogene reports patient death in Rett syndrome trial - Investing.com
Neurogene reports patient death in Rett syndrome trial By Investing.com - Investing.com Australia
Neurogene Adjusts Clinical Trial After Setback - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Investors to Learn More About the Investigation - AccessWire
Leerink Partnrs Forecasts Reduced Earnings for Neurogene - MarketBeat
FY2024 EPS Estimates for Neurogene Cut by William Blair - MarketBeat
FY2024 EPS Estimates for Neurogene Raised by HC Wainwright - MarketBeat
Stifel stays positive on Neurogene stock amid regulatory clarity on Rett trial - Investing.com
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene price target lowered to $45 from $60 at BMO Capital - TipRanks
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More - BioSpace
Finanzdaten der Neurogene Inc-Aktie (NGNE)
Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Neurogene Inc-Aktie (NGNE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Nov 22 '24 |
Buy |
20.48 |
24,000 |
491,400 |
76,844 |
| McMinn Rachel | Chief Executive Officer |
Nov 22 '24 |
Buy |
20.40 |
47,500 |
969,000 |
1,297,859 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):